Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Tax Assets

Deferred tax assets that can reduce taxes payable in future periods.

Grifols, S.A.NASDAQ: GRFS

Tax Assets · Q2 FY2026 · quarter ended Jun 2026

Tax assets rises 24.3% from a year ago

Tax assets stood at €476M at the end of Q2 FY2026, up 24.3% from a year earlier. Over 3 fiscal years it compounded at +38.2% a year.

Context

  • Tax assets amounted to 2.4% of total assets at the end of Q2 FY2026, up 0.4 pp from a year earlier.
  • Tax assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether tax assets keeps rising in the next quarterly balance sheet after a +24.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€476M— QoQ
Last fiscal yearDec 2025
€461.8M+35.2% YoY
Year agoJun 2025
€383.04M+24.3% since
Tax Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.3%——
1 year+35.2%——
3-year CAGR+38.2%——
5-year CAGR——
10-year CAGR——

Tax Assets history

EUR · from the balance sheet

Latest · FY2025
461.8M EUR
Year-over-year change
+35.2%

Tax Assets vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so tax assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +24.3% is the highest of 3, against a peer median of +4.3%.
  • Tax assets amounts to 2.4% of total assets for GRFS, versus a peer median of 0.0%.
GRFS Competitors
Tax Assets for GRFS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GRFSGrifols, S.A.Jun 2026€476M EUR+24.3%+38.2%2.4%
ADMAADMA Biologics, Inc.Jun 2026$69.97M USD-11.7%—10.2%
HAEHaemonetics CorporationJun 2026$9.43M USD+20.3%+22.0%0.4%
ABTAbbott LaboratoriesJun 2026$0 USD——0.0%
BDXBecton, Dickinson and CompanySep 2026$0 USD——0.0%
TECHBio-Techne CorporationSep 2026$0 USD——0.0%
BIOBio-Rad Laboratories, Inc.Jun 2026$0 USD——0.0%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$0 USD——0.0%
QDELQuidelOrtho CorporationMar 2026$0 USD——0.0%
Peer median (excluding GRFS) —+4.3%+22.0%0.0%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents655.49M549.21M529.58M979.78M824.65M
Short-term Investments2.03B31.03M116.47M21.18M0
Net Receivables434.14M774.2M692.86M1.08B844.64M
Inventory2.26B3.24B3.48B3.56B3.29B
Other Current Assets131.63M80.88M1.31B78.58M100.96M
Total Current Assets5.51B4.69B6.13B5.73B5.07B
Property, Plant & Equipment (Net)3.34B4.28B4.19B4.31B4.05B
Goodwill6.23B7.01B6.8B7.4B6.83B
Intangible Assets1B2.95B1.21B2.93B2.73B
Long-term Investments2.27B1.99B451.9M528.97M592.75M
Tax Assets0174.92M0341.67M461.8M
Other Non-current Assets882.61M124.19M2.21B167.72M15.99M
Total Non-current Assets13.72B16.54B14.86B15.68B14.68B
Total Assets19.23B21.23B20.99B21.41B19.75B
Account Payables628.99M787.96M822.95M852.31M840.64M
Short-term Debt2.35B578.92M916.51M523.13M385.84M
Tax Payables015.69M084.99M0
Deferred Revenue037.83M070.87M76.97M
Other Current Liabilities119.44M381.59M108.6M81.95M459.8M
Total Current Liabilities3.47B2.02B2.33B2.16B2.02B
Long-term Debt6.94B8.15B8.99B8.42B7.39B
Deferred Tax Liabilities01.03B01.01B906.61M
Deferred Revenue (Non-current)015.12M013.94M0
Other Non-current Liabilities675.34M1.12B1.16B170.46M854.64M
Total Non-current Liabilities8.44B11.23B11.15B10.64B10.12B
Total Liabilities11.92B13.25B13.48B12.8B12.13B
Common Stock119.6M119.6M119.6M119.6M119.95M
Retained Earnings248M079.36M156.92M0
Accumulated OCI4.41B4.78B4.41B4.83B4.37B
Other Stockholders Equity00000
Minority Interest1.79B2.33B2.15B2.72B2.33B
Total Equity7.32B7.98B7.51B8.61B7.6B
Total Debt10.17B9.75B11.02B10.09B8.74B
Net Debt9.51B9.2B10.49B9.11B7.92B

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.